A61K 47/6807
The drug or compound being a sugar, nucleoside, nucleotide, nucleic acid
Official title: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
A61K47/6807 (The drug or compound being a sugar, nucleoside, nucleotide, nucleic acid) appears on 750 US grants and 1,347 published applications in this corpus.
Search patents in A61K- Granted patents
- 750
- Published applications
- 1,347
- Assignees
- 455
- Inventors
- 2,264
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 17 | 0 |
| 1999 | 10 | 0 |
| 2000 | 9 | 0 |
| 2001 | 7 | 0 |
| 2002 | 6 | 8 |
| 2003 | 9 | 14 |
| 2004 | 3 | 20 |
| 2005 | 4 | 21 |
| 2006 | 6 | 17 |
| 2007 | 4 | 21 |
| 2008 | 4 | 14 |
| 2009 | 12 | 36 |
| 2010 | 12 | 22 |
| 2011 | 10 | 37 |
| 2012 | 14 | 20 |
| 2013 | 21 | 26 |
| 2014 | 20 | 44 |
| 2015 | 25 | 56 |
| 2016 | 41 | 58 |
| 2017 | 36 | 76 |
| 2018 | 43 | 89 |
| 2019 | 50 | 78 |
| 2020 | 42 | 63 |
| 2021 | 56 | 95 |
| 2022 | 44 | 90 |
| 2023 | 60 | 119 |
| 2024 | 57 | 119 |
| 2025 | 65 | 128 |
| 2026 | 31 | 76 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Muscle-targeting complexes and uses thereof22 Sep 2026US 12,742,007 B2Dyne Therapeutics, Inc.
- CD38 antibody drug conjugate15 Sep 2026US 12,734,209 B2Ogory, Inc.
- Immune cell receptor antibodies conjugated to high affinity siglec-ligands8 Sep 2026US 12,728,169 B2The Scripps Research Institute
- Non-viral immuno-targeting1 Sep 2026US 12,721,900 B2University of Washington
- Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives8 Oct 2026US 2026/0306652 A1Merck Sharp & Dohme Corp.
- Anti-HER2 Antibodies and Immunoconjugates1 Oct 2026US 2026/0297214 A1Genentech, Inc.
- Enzymatic Removable Cell Penetration-Blocker (rCPB) Conjugated To A Tandem Peptide-Cytotoxin, Tandem Peptide-miRNA Chimeric Molecules Or Tandem Peptide-Antioncogenic miRNA For Targeted Cancer Cell Delivery, Off-Target Toxicity Minimization, Resistance Reduction, Gene Regulation, Anti-Tumor Immune Response Upregulation In The Tumor Microenvironment And Systemically, And Synergistic Enhancement Of Anti-Tumor Activity24 Sep 2026US 2026/0284217 A1
- Trogocytosis in cancer cells and methods for treating cancer related thereto17 Sep 2026US 2026/0274990 A1Arizona Board of Regents on Behalf of the University of Arizona
- Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells17 Sep 2026US 2026/0274997 A1Denali Therapeutics Inc.
Most cited
By later US patents
- Lysosomal enzyme-cleavable antitumor drug conjugates653US 6,214,345 B1Bristol-Myers Squibb Company · 2001
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates493US 5,714,586 AAmerican Cyanamid Company · 1998
- Therapeutic inhibitor of vascular smooth muscle cells438US 5,981,568 ANeoRx Corporation · 1999
- Conjugates of methyltrithio antitumor agents and intermediates for their synthesis437US 5,773,001 AAmerican Cyanamid Company · 1998